Richardson, TX, May 24, 2019 --(PR.com
)-- The Dallas based research company plans to roll out a new clinical rating training program, Pillar Precision. The program includes a clinician guide featuring best practices for specific CNS indications, placebo response training, malingering detection, data-driven decision making, and multi-site rating consultation for difficult cases. The goal of Pillar Precision is to minimize the placebo response, select appropriate participants, detect relevant clinical changes, and calibrate sites under a unified approach.
Dr. Sarah Neubauer, who will be leading the initiative within the company stated, “I am excited to be a part of this innovative program and contribute to the Pillar team. The Pillar team has had great success in Acute Schizophrenia trials, and their separation from placebo over the past 10 years has been unprecedented. Studying this historical data, rating techniques, and interviewing the clinical team for CNS indications is providing a new approach for best practices that will benefit the industry.”
Brian Craig, CEO and sub-investigator rater, says, “The launch of Pillar Precision is a landmark event in our company and our industry. Dr. Neubauer is formalizing and systemizating the internal rating practices that have made Pillar the industry leader in Acute Schizophrenia trials. Sponsors can count on our psychometric rating expertise across our company and this is opening the door for new study design approaches and trial efficiencies. This program has been a long time in development, and it is satisfying to see it come to fruition.”
Pillar Clinical Research was originally founded in Texas 2006. The company has set itself apart through best in class research services as well as a focus on participant care. Pillar Clinical Research is proud of a long history of collaboration with CROs, industry vendors, and clinical based technology providers. Please visit pillarcr.com to learn more about the organization and how they may be able to serve you!